Interprofessional approach to personalized medication management and therapy optimization in IBD care
A considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug–drug interactions. Also, the disease’s impact often leads to the consumption of additional self-medication by th...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1446695/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582874215219200 |
|---|---|
| author | Daniel Fleischmann Benedicta Binder Muriel Huss Tanja Elger Claudia Wolf Johanna Loibl Hauke Christian Tews Arne Kandulski Stephan Schmid Martina Müller Alexander Kratzer |
| author_facet | Daniel Fleischmann Benedicta Binder Muriel Huss Tanja Elger Claudia Wolf Johanna Loibl Hauke Christian Tews Arne Kandulski Stephan Schmid Martina Müller Alexander Kratzer |
| author_sort | Daniel Fleischmann |
| collection | DOAJ |
| description | A considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug–drug interactions. Also, the disease’s impact often leads to the consumption of additional self-medication by the patients such as naturopathic remedies to alleviate disease-induced suffering and nutritional supplements to compensate for malabsorption syndromes inherent to the condition. There is a well-established consensus that polymedication coupled with unregulated supplementary intake can jeopardize the safety of drug therapy. Despite this, pharmaceutical co-supervision—proven to mitigate adverse drug events and enhance patient adherence to treatment—is generally lacking in routine clinical settings. Furthermore, the assessment of individual therapy adherence, a crucial predictive factor for therapeutic outcomes, is frequently suboptimal. In response to these issues, this study implemented an interdisciplinary approach wherein a team comprising medical and pharmaceutical professionals conducted a comprehensive survey coupled with a medication review for patients attending an IBD outpatient clinic. Employing an IBD-specific questionnaire alongside the patients’ documented medication regimens enabled the identification and subsequent discussion of current therapeutic concerns and potential medication-related risks during follow-up consultations. This intervention aimed to bolster individual patient satisfaction and enhance medication safety, ultimately fostering sustained success in IBD management. |
| format | Article |
| id | doaj-art-81cce298dddf4ced9fb8132f0202a6e9 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-81cce298dddf4ced9fb8132f0202a6e92025-01-29T06:46:14ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.14466951446695Interprofessional approach to personalized medication management and therapy optimization in IBD careDaniel Fleischmann0Benedicta Binder1Muriel Huss2Tanja Elger3Claudia Wolf4Johanna Loibl5Hauke Christian Tews6Arne Kandulski7Stephan Schmid8Martina Müller9Alexander Kratzer10Hospital Pharmacy, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, GermanyHospital Pharmacy, University Hospital Regensburg, Regensburg, GermanyA considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug–drug interactions. Also, the disease’s impact often leads to the consumption of additional self-medication by the patients such as naturopathic remedies to alleviate disease-induced suffering and nutritional supplements to compensate for malabsorption syndromes inherent to the condition. There is a well-established consensus that polymedication coupled with unregulated supplementary intake can jeopardize the safety of drug therapy. Despite this, pharmaceutical co-supervision—proven to mitigate adverse drug events and enhance patient adherence to treatment—is generally lacking in routine clinical settings. Furthermore, the assessment of individual therapy adherence, a crucial predictive factor for therapeutic outcomes, is frequently suboptimal. In response to these issues, this study implemented an interdisciplinary approach wherein a team comprising medical and pharmaceutical professionals conducted a comprehensive survey coupled with a medication review for patients attending an IBD outpatient clinic. Employing an IBD-specific questionnaire alongside the patients’ documented medication regimens enabled the identification and subsequent discussion of current therapeutic concerns and potential medication-related risks during follow-up consultations. This intervention aimed to bolster individual patient satisfaction and enhance medication safety, ultimately fostering sustained success in IBD management.https://www.frontiersin.org/articles/10.3389/fmed.2025.1446695/fullinflammatory bowel diseasepatient safetyclinical pharmaceutical careinterprofessional collaborationmedication management |
| spellingShingle | Daniel Fleischmann Benedicta Binder Muriel Huss Tanja Elger Claudia Wolf Johanna Loibl Hauke Christian Tews Arne Kandulski Stephan Schmid Martina Müller Alexander Kratzer Interprofessional approach to personalized medication management and therapy optimization in IBD care Frontiers in Medicine inflammatory bowel disease patient safety clinical pharmaceutical care interprofessional collaboration medication management |
| title | Interprofessional approach to personalized medication management and therapy optimization in IBD care |
| title_full | Interprofessional approach to personalized medication management and therapy optimization in IBD care |
| title_fullStr | Interprofessional approach to personalized medication management and therapy optimization in IBD care |
| title_full_unstemmed | Interprofessional approach to personalized medication management and therapy optimization in IBD care |
| title_short | Interprofessional approach to personalized medication management and therapy optimization in IBD care |
| title_sort | interprofessional approach to personalized medication management and therapy optimization in ibd care |
| topic | inflammatory bowel disease patient safety clinical pharmaceutical care interprofessional collaboration medication management |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1446695/full |
| work_keys_str_mv | AT danielfleischmann interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT benedictabinder interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT murielhuss interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT tanjaelger interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT claudiawolf interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT johannaloibl interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT haukechristiantews interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT arnekandulski interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT stephanschmid interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT martinamuller interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare AT alexanderkratzer interprofessionalapproachtopersonalizedmedicationmanagementandtherapyoptimizationinibdcare |